Design Development and Evaluation of Ocular Gel containing Gatifloxacin to treat Endopthalamitis

Author(s)

Kamble, S.A., Kumbhar, P.V.

Author's Affiliation

Abstract

Development of ocular drug delivery system has been major challenging and demanding task for delivery of drug into the eye due to its static and dynamic barriers. Therefore rationale drug delivery has to be developed to overcome the drawbacks of established conventional and nonconventional dosage forms. Most of ocular dosage forms are applied topically and there is no need of crossing the ocular barriers in such cases. Therefore significant therapeutic effect is shown by the drug when given by topical route. Endopthalamitis is inflammation of one or more coats of the eye and adjacent cavities and is an uncommon but potentially sight-threatening condition that varies geographically in incidence and in cause. It is the inflammation involving entire eye. There are two types of Endopthalamitis viz. exogenous and endogenous. The causative organisms are Staphylococcus aureus S. epidermidis mainly. Drugs are given intravitreally, systemically and topically. Among them the topical gel are intended to increase patient compliance and promptly release the drug for effective and complete eradication of causative microorganisms is possible. Gatifloxacin having bactericidal action against strains of bacteria and but  it is given in treatment of endopthalamitis in the form of ophthalmic solution Therefore ophthalmic gel containing drug PF-127 and PEG was developed and evaluated to overcome the drawbacks of ophthalmic solution as a dosage form

Keywords

Endopthalamitis, Gatifloxacin, Ocular gel, Pluronic F-12

Cite This Article

Kamble, S.A., Kumbhar, P.V. (2018). Design Development and Evaluation of Ocular Gel containing Gatifloxacin to treat Endopthalamitis. International Journal for Pharmaceutical Research Scholars (IJPRS), 7(1), 96-106.